Performance on the balloon analogue risk task and anticipatory response inhibition task is associated with severity of impulse control behaviours in people with Parkinson's disease.
Anticipatory response inhibition task
Balloon analogue risk task
Dopamine agonists
Dopamine genetic risk score
Impulse control disorders
Parkinson’s disease
Questionnaire for impulsive-compulsive behaviours in Parkinson’s disease
Journal
Experimental brain research
ISSN: 1432-1106
Titre abrégé: Exp Brain Res
Pays: Germany
ID NLM: 0043312
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
10
2022
accepted:
24
02
2023
medline:
11
4
2023
pubmed:
10
3
2023
entrez:
9
3
2023
Statut:
ppublish
Résumé
Dopamine agonist medication is one of the largest risk factors for development of problematic impulse control behaviours (ICBs) in people with Parkinson's disease. The present study investigated the potential of dopamine gene profiling and individual performance on impulse control tasks to explain ICB severity. Clinical, genetic and task performance data were entered into a mixed-effects linear regression model for people with Parkinson's disease taking (n = 50) or not taking (n = 25) dopamine agonist medication. Severity of ICBs was captured via the Questionnaire for Impulsive-compulsive disorders in Parkinson's disease Rating Scale. A cumulative dopamine genetic risk score (DGRS) was calculated for each participant from variance in five dopamine-regulating genes. Objective measures of impulsive action and impulsive choice were measured on the Anticipatory Response Inhibition Task and Balloon Analogue Risk Task, respectively. For participants on dopamine agonist medication, task performance reflecting greater impulsive choice (p = 0.014), and to a trend level greater impulsive action (p = 0.056), as well as a longer history of DA medication (p < 0.001) all predicted increased ICB severity. DGRS however, did not predict ICB severity (p = 0.708). No variables could explain ICB severity in the non-agonist group. Our task-derived measures of impulse control have the potential to predict ICB severity in people with Parkinson's and warrant further investigation to determine whether they can be used to monitor ICB changes over time. The DGRS appears better suited to predicting the incidence, rather than severity, of ICBs on agonist medication.
Identifiants
pubmed: 36894682
doi: 10.1007/s00221-023-06584-y
pii: 10.1007/s00221-023-06584-y
pmc: PMC10082127
doi:
Substances chimiques
Dopamine Agonists
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1159-1172Informations de copyright
© 2023. The Author(s).
Références
Abidin SZ, Tan EL, Chan SC, Jaafar A, Lee AX, Abd Hamid MHN, Abdul Murad NA, Pakarul Razy NF, Azmin S, Ahmad Annuar A, Lim SY, Cheah PS, Ling KH, Mohamed Ibrahim N (2015) DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson’s disease patients. BMC Neurol 15(1):1–10. https://doi.org/10.1186/s12883-015-0316-2
doi: 10.1186/s12883-015-0316-2
Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ (2013) Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord 28(3):327–333. https://doi.org/10.1002/mds.25291
doi: 10.1002/mds.25291
pubmed: 23283708
pmcid: 3894820
Callesen MB, Weintraub D, Damholdt MF, Møller A (2014) Impulsive and compulsive behaviors among Danish patients with Parkinson’s disease: Prevalence, depression, and personality. Parkinsonism Relat Disord 20(1):22–26. https://doi.org/10.1016/j.parkreldis.2013.09.006
doi: 10.1016/j.parkreldis.2013.09.006
pubmed: 24090948
Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, Volonté MA, Antonini A, Perani D (2017) Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson’s disease. NeuroImage Clin 14:734–740. https://doi.org/10.1016/j.nicl.2017.03.011
doi: 10.1016/j.nicl.2017.03.011
pubmed: 28409113
pmcid: 5379906
Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, Pezzoli G, Antonini A, Strafella AP (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 39(1):98–104. https://doi.org/10.1016/j.nbd.2010.03.013
doi: 10.1016/j.nbd.2010.03.013
pubmed: 20338240
Claassen DO, van den Wildenberg WPM, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, Wylie SA (2011) The Risky Business of Dopamine Agonists in Parkinson Disease and Impulse Control Disorders. Behavioural Neuroscience 125(4):492–500. https://doi.org/10.1037/a0023795.The
doi: 10.1037/a0023795.The
Claassen DO, Van Den Wildenberg WPM, Harrison MB, Van Wouwe NC, Kanoff K, Neimat JS, Wylie SA (2015) Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. Pharmacol Biochem Behav 129:19–25. https://doi.org/10.1016/j.pbb.2014.11.017
doi: 10.1016/j.pbb.2014.11.017
pubmed: 25459105
Claassen DO, Stark AJ, Spears CA, Petersen KJ, van Wouwe NC, Kessler RM, Zald DH, Donahue MJ (2017) Mesocorticolimbic hemodynamic response in Parkinson’s disease patients with compulsive behaviors. Mov Disord 32(11):1574–1583. https://doi.org/10.1002/mds.27047
doi: 10.1002/mds.27047
pubmed: 28627133
pmcid: 5681361
Congdon E, Constable RT, Lesch KP, Canli T (2009) Influence of SLC6A3 and COMT variation on neural activation during response inhibition. Biol Psychol 81(3):144–152. https://doi.org/10.1016/j.biopsycho.2009.03.005
doi: 10.1016/j.biopsycho.2009.03.005
pubmed: 19482231
pmcid: 2689843
Cools R (2006) Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev 30:1–23. https://doi.org/10.1016/j.neubiorev.2005.03.024
doi: 10.1016/j.neubiorev.2005.03.024
pubmed: 15935475
Cools R, Barker RA, Sahakian BJ, Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex 11(12):1136–1143. https://doi.org/10.1093/cercor/11.12.1136
doi: 10.1093/cercor/11.12.1136
pubmed: 11709484
Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Elbaz A (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91(3):e189–e201. https://doi.org/10.1212/WNL.0000000000005816
doi: 10.1212/WNL.0000000000005816
pubmed: 29925549
pmcid: 6059034
Cunnington R, Iansek R, Bradshaw JL, Phillips JG (1995) Movement- related potentials in Parkinson’s disease. Presence and predictability of temporal and spatial cues. Brain 118(4):935–950. https://doi.org/10.1093/brain/118.4.935
doi: 10.1093/brain/118.4.935
pubmed: 7655889
Dauer W, Przedborski S (2003) Models and mechanisms. Neuron 39:889–909. https://doi.org/10.1016/s0896-6273(03)00568-3
doi: 10.1016/s0896-6273(03)00568-3
pubmed: 12971891
Erga AH, Dalen I, Ushakova A, Chung J, Tzoulis C, Tysnes OB, Alves G, Pedersen KF, Maple-Grødem J (2018) Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson’s disease. Front Neurol. https://doi.org/10.3389/fneur.2018.00109
doi: 10.3389/fneur.2018.00109
pubmed: 29872418
pmcid: 5972311
Faouzi J, Couvy-Duchesne B, Bekadar S, Colliot O, Corvol JC (2021) Exploratory analysis of the genetics of impulse control disorders in Parkinson’s disease using genetic risk scores. Parkinsonism Relat Disord 86:74–77. https://doi.org/10.1016/j.parkreldis.2021.04.003
doi: 10.1016/j.parkreldis.2021.04.003
pubmed: 33872999
Filip P, Linhartová P, Hlavatá P, Šumec R, Baláž M, Bareš M, Kašpárek T (2018) Disruption of multiple distinctive neural networks associated with impulse control disorder in Parkinson’s disease. Front Hum Neurosci 12:462. https://doi.org/10.3389/fnhum.2018.00462
doi: 10.3389/fnhum.2018.00462
pubmed: 30519167
pmcid: 6258801
Ford CP (2014) The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 282:13–22. https://doi.org/10.1016/j.neuroscience.2014.01.025
doi: 10.1016/j.neuroscience.2014.01.025
pubmed: 24463000
Gasser T, Wichmann T, DeLong MR (2015) parkinson disease and other synucleinopathies. Neurobiology of brain disorders: biological basis of neurological and psychiatric disorders. Elsevier, pp 281–302
doi: 10.1016/B978-0-12-398270-4.00019-7
Gatto EM, Aldinio V (2019) Impulse control disorders in parkinson’s disease. A brief and comprehensive review. Front Neurol. https://doi.org/10.3389/fneur.2019.00351
doi: 10.3389/fneur.2019.00351
pubmed: 31057473
pmcid: 6481351
Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21(5):501–506. https://doi.org/10.1177/0269881106073109
doi: 10.1177/0269881106073109
pubmed: 17446202
Goerlich-Dobre KS, Probst C, Winter L, Witt K, Deuschl G, Möller B, Van Eimeren T (2014) Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord 29(2):214–220. https://doi.org/10.1002/mds.25679
doi: 10.1002/mds.25679
pubmed: 24123483
Gualtieri CT, Johnson LG (2006) Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 21(7):623–643. https://doi.org/10.1016/j.acn.2006.05.007
doi: 10.1016/j.acn.2006.05.007
pubmed: 17014981
Hall A, Weaver SR, Compton LJ, Byblow WD, Jenkinson N, MacDonald HJ (2021) Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease. Clin Parkinsonism Relat Disord 5:1113. https://doi.org/10.1016/j.prdoa.2021.100113
doi: 10.1016/j.prdoa.2021.100113
Hlavatá P, Linhartová P, Šumec R, Filip P, Světlák M, Baláž M, Kašpárek T, Bareš M (2020) Behavioral and Neuroanatomical Account of Impulsivity in Parkinson’s Disease. Front Neurol. https://doi.org/10.3389/fneur.2019.01338
doi: 10.3389/fneur.2019.01338
pubmed: 31998210
pmcid: 6965152
Housden CR, O’Sullivan SS, Joyce EM, Lees AJ, Roiser JP (2010) Intact reward learning but elevated delay discounting in Parkinson’s disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 35(11):2155–2164. https://doi.org/10.1038/npp.2010.84
doi: 10.1038/npp.2010.84
pubmed: 20631686
pmcid: 3055316
Hovde MJ, Larson GH, Vaughan RA, Foster JD (2019) Model systems for analysis of dopamine transporter function and regulation. Neurochem Int 123:13–21. https://doi.org/10.1016/j.neuint.2018.08.015
doi: 10.1016/j.neuint.2018.08.015
pubmed: 30179648
Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC, Corvol JC, Elbaz A, Vidailhet M, Brice A, Artaud F, Bourdain F, Faurie-Grepon A (2020) Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study. Parkinsonism Relat Disord 75:30–33. https://doi.org/10.1016/j.parkreldis.2020.03.017
doi: 10.1016/j.parkreldis.2020.03.017
pubmed: 32450545
Isaias IU, Siri C, Cilia R, de Gaspari D, Pezzoli G, Antonini A (2008) The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord 23(3):411–415. https://doi.org/10.1002/mds.21872
doi: 10.1002/mds.21872
pubmed: 18067187
Jahanshahi M, Jenkins H, Brown RG, Marsden CD, Passingham RE, Brooks DJ (1996) Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson’s disease subjects. Brain 119(3):1045–1048. https://doi.org/10.1093/brain/119.3.1045
doi: 10.1093/brain/119.3.1045
Joutsa J, Martikainen K, Vahlberg T, Kaasinen V (2012) Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 18(10):1079–1083. https://doi.org/10.1016/j.parkreldis.2012.06.005
doi: 10.1016/j.parkreldis.2012.06.005
pubmed: 22784693
Kelly MJ, Baig F, Hu MTM, Okai D (2020) Spectrum of impulse control behaviours in Parkinson’s disease: Pathophysiology and management. J Neurol Neurosurg Psychiatry 91:703–711. https://doi.org/10.1136/jnnp-2019-322453
doi: 10.1136/jnnp-2019-322453
pubmed: 32354771
Ko JH, Antonelli F, Monchi O, Ray N, Rusjan P, Houle S, Lang AE, Christopher L, Strafella AP (2013) Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson’s disease. Hum Brain Mapp 34(7):1591–1604. https://doi.org/10.1002/hbm.22006
doi: 10.1002/hbm.22006
pubmed: 22331665
Kraemmer J, Smith K, Weintraub D, Guillemot V, Nalls MA, Cormier-Dequaire F, Moszer I, Brice A, Singleton AB, Corvol JC (2016) Clinical-genetic model predicts incident impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry 87(10):1106–1111. https://doi.org/10.1136/jnnp-2015-312848
doi: 10.1136/jnnp-2015-312848
pubmed: 27076492
Krieger DM, Cardoso SV, Caumo W, Valença G, Weintraub D, de Rieder CR, M. (2017) Parkinson’s disease impulsive-compulsive disorders questionnaire - current short (QUIP-CS) - translation and validation of content of Portuguese version. J Bras Psiquiatr 66(2):111–115. https://doi.org/10.1590/0047-2085000000158
doi: 10.1590/0047-2085000000158
Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, Jeon BS (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord 24(12):1803–1810. https://doi.org/10.1002/mds.22678
doi: 10.1002/mds.22678
pubmed: 19562769
Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ, Jeon BS (2010) Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 16(3):202–207. https://doi.org/10.1016/j.parkreldis.2009.12.002
doi: 10.1016/j.parkreldis.2009.12.002
pubmed: 20018549
Leeman RF, Potenza MN (2011) Impulse control disorders in Parkinson’s disease: clinical characteristics and implications. Neuropsychiatry 1:133–147. https://doi.org/10.2217/npy.11.11
doi: 10.2217/npy.11.11
pubmed: 21709778
pmcid: 3120055
Lepack AE, Werner CT, Stewart AF, Fulton SL, Zhong P, Farrelly LA, Smith ACW, Ramakrishnan A, Lyu Y, Bastle RM, Martin JA, Mitra S, O’Connor RM, Wang ZJ, Molina H, Turecki G, Shen L, Yan Z, Calipari ES, Maze I (2020) Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking. Science 368(6487):197–201. https://doi.org/10.1126/science.aaw8806
doi: 10.1126/science.aaw8806
pubmed: 32273471
pmcid: 7228137
Logan GD, Cowan WB, Davis KA (1984) On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform 10(2):276–291. https://doi.org/10.1037/0096-1523.10.2.276
doi: 10.1037/0096-1523.10.2.276
pubmed: 6232345
MacDonald HJ, Stinear CM, Ren A, Coxon JP, Kao J, Macdonald L, Snow B, Cramer SC, Byblow WD (2016) Dopamine gene profiling to predict impulse control and effects of dopamine agonist ropinirole. J Cogn Neurosci 28(7):909–919. https://doi.org/10.1162/jocn
doi: 10.1162/jocn
pubmed: 26942320
Marín-Lahoz J, Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, Pascual-Sedano B, Pérez-Pérez J, Gironell A, Kulisevsky J (2018) Parkinson’s disease: impulsivity does not cause impulse control disorders but boosts their severity. Front Psychiatry. https://doi.org/10.3389/fpsyt.2018.00465
doi: 10.3389/fpsyt.2018.00465
pubmed: 30323775
pmcid: 6172299
Marković V, Stanković I, Petrović I, Stojković T, Dragašević-Mišković N, Radovanović S, Svetel M, Stefanova E, Kostić V (2020) Dynamics of impulsive–compulsive behaviors in early Parkinson’s disease: a prospective study. J Neurol 267(4):1127–1136. https://doi.org/10.1007/s00415-019-09692-4
doi: 10.1007/s00415-019-09692-4
pubmed: 31902006
Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F (2019) French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS). Parkinsonism Relat Disord 63:117–123. https://doi.org/10.1016/j.parkreldis.2019.02.026
doi: 10.1016/j.parkreldis.2019.02.026
pubmed: 30862454
Martini A, Ellis SJ, Grange JA, Tamburin S, Dal Lago D, Vianello G, Edelstyn NMJ (2018) Risky decision-making and affective features of impulse control disorders in Parkinson’s disease. J Neural Transm 125(2):131–143. https://doi.org/10.1007/s00702-017-1807-7
doi: 10.1007/s00702-017-1807-7
pubmed: 29119257
Mata R, Hau R, Papassotiropoulos A, Hertwig R (2012) DAT1 polymorphism is associated with risk taking in the Balloon Analogue Risk Task (BART). PLoS ONE. https://doi.org/10.1371/journal.pone.0039135
doi: 10.1371/journal.pone.0039135
pubmed: 23118923
pmcid: 3485262
Meder D, Herz DM, Rowe JB, Lehéricy S, Siebner HR (2019) The role of dopamine in the brain - lessons learned from Parkinson’s disease. Neuroimage 190:79–93. https://doi.org/10.1016/j.neuroimage.2018.11.021
doi: 10.1016/j.neuroimage.2018.11.021
pubmed: 30465864
Nikolova YS, Ferrell RE, Manuck SB, Hariri AR (2011) Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity. Neuropsychopharmacology 36(9):1940–1947. https://doi.org/10.1038/npp.2011.82
doi: 10.1038/npp.2011.82
pubmed: 21593733
pmcid: 3154113
Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17(3):153–155. https://doi.org/10.1016/j.parkreldis.2010.11.015
doi: 10.1016/j.parkreldis.2010.11.015
pubmed: 21186135
Pearson-Fuhrhop KM, Minton B, Acevedo D, Shahbaba B, Cramer SC (2013) Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa. PLoS ONE 8(4):e61197. https://doi.org/10.1371/journal.pone.0061197
doi: 10.1371/journal.pone.0061197
pubmed: 23613810
pmcid: 3629211
Pearson-Fuhrhop KM, Dunn EC, Mortero S, Devan WJ, Falcone GJ, Lee P, Holmes AJ, Hollinshead MO, Roffman JL, Smoller JW, Rosand J, Cramer SC (2014) Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression. PLoS ONE 9(5):e93772. https://doi.org/10.1371/journal.pone.0093772
doi: 10.1371/journal.pone.0093772
pubmed: 24834916
pmcid: 4023941
Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O (2012) Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with parkinson disease. Clin Neuropharmacol 35(6):261–265. https://doi.org/10.1097/WNF.0b013e31826e6e6d
doi: 10.1097/WNF.0b013e31826e6e6d
pubmed: 23123689
Probst CC, Winter LM, Möller B, Weber H, Weintraub D, Witt K, Deuschl G, Katzenschlager R, Van Eimeren T (2014) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol Neurosurg Psychiatry 261:936–942. https://doi.org/10.1007/s00415-014-7299-6
doi: 10.1007/s00415-014-7299-6
Ray NJ, Brittain JS, Holland P, Joundi RA, Stein JF, Aziz TZ, Jenkinson N (2012) The role of the subthalamic nucleus in response inhibition: Evidence from local field potential recordings in the human subthalamic nucleus. Neuroimage 60(1):271–278. https://doi.org/10.1016/j.neuroimage.2011.12.035
doi: 10.1016/j.neuroimage.2011.12.035
pubmed: 22209815
Ricciardi L, Haggard P, de Boer L, Sorbera C, Stenner MP, Morgante F, Edwards MJ (2017) Acting without being in control: Exploring volition in Parkinson’s disease with impulsive compulsive behaviours. Parkinsonism Relat Disord 40:51–57. https://doi.org/10.1016/j.parkreldis.2017.04.011
doi: 10.1016/j.parkreldis.2017.04.011
pubmed: 28478995
Ruitenberg MFL, van Wouwe NC, Wylie SA, Abrahamse EL (2021) The role of dopamine in action control: insights from medication effects in Parkinson’s disease. Neurosci Biobehav Rev 127:158–170. https://doi.org/10.1016/j.neubiorev.2021.04.023
doi: 10.1016/j.neubiorev.2021.04.023
pubmed: 33905788
Seeman P (2015) parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69(4):183–189. https://doi.org/10.1002/syn.21805
doi: 10.1002/syn.21805
pubmed: 25645960
Sinha N, Manohar S, Husain M (2013) Impulsivity and apathy in Parkinson’s disease. J Neuropsychol 7(2):255–283. https://doi.org/10.1111/jnp.12013
doi: 10.1111/jnp.12013
pubmed: 23621377
Smith KM, Xie SX, Weintraub D (2016) Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry 87(8):864–870. https://doi.org/10.1136/jnnp-2015-311827
doi: 10.1136/jnnp-2015-311827
pubmed: 26534930
Takahashi M, Koh J, Yorozu S, Kajimoto Y, Nakayama Y, Sakata M, Yasui M, Hiwatani Y, Weintraub D, Ito H (2022) Validation of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS). Parkinson’s Disease. https://doi.org/10.1155/2022/1503167
doi: 10.1155/2022/1503167
pubmed: 35371432
pmcid: 8967585
Trantham-Davidson H, Neely LC, Lavin A, Seamans JK (2004) Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 24(47):10652–10659. https://doi.org/10.1523/JNEUROSCI.3179-04.2004
doi: 10.1523/JNEUROSCI.3179-04.2004
pubmed: 15564581
pmcid: 5509068
Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler R (2013) Dopamine overdose hypothesis: evidence and clinical implications. Mov Disord 28:1920–1929. https://doi.org/10.1002/mds.25687
doi: 10.1002/mds.25687
pubmed: 24123087
Vela L, Martínez Castrillo JC, García Ruiz P, Gasca-Salas C, Macías Macías Y, Pérez Fernández E, Ybot I, Lopez Valdés E, Kurtis MM, Posada Rodriguez IJ, Mata M, Ruiz Huete C, Eimil M, Borrue C, del Val J, López-Manzanares L, Rojo Sebastian A, Marasescu R (2016) The high prevalence of impulse control behaviors in patients with early-onset Parkinson’s disease: a cross-sectional multicenter study. J Neurol Sci 368:150–154. https://doi.org/10.1016/j.jns.2016.07.003
doi: 10.1016/j.jns.2016.07.003
pubmed: 27538621
Verbruggen F, Aron AR, Band GP, Beste C, Bissett PG, Brockett AT, Brown JW, Chamberlain SR, Chambers CD, Colonius H, Colzato LS, Corneil BD, Coxon JP, Dupuis A, Eagle DM, Garavan H, Greenhouse I, Heathcote A, Huster RJ, Boehler CN (2019) A consensus guide to capturing the ability to inhibit actions and impulsive behaviors in the stop-signal task. Elife 8:1–26. https://doi.org/10.7554/elife.46323
doi: 10.7554/elife.46323
Vriend C, Nordbeck AH, Booij J, van der Werf YD, Pattij T, Voorn P, Raijmakers P, Foncke EMJ, van de Giessen E, Berendse HW, van den Heuvel OA (2014) Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord 29(7):904–911. https://doi.org/10.1002/mds.25886
doi: 10.1002/mds.25886
pubmed: 24832846
Vriend C, Leffa DT, Trujillo JP, Gerrits NJHM, de Boer FE, Berendse HW, van der Werf YD, van den Heuvel OA (2018) Functional connectivity alterations in Parkinson’s disease during the stop-signal task. BioRxiv, April. https://doi.org/10.1101/304584
doi: 10.1101/304584
Weintraub D (2008) Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 64(SUPPL. 2):93–100. https://doi.org/10.1002/ana.21454
doi: 10.1002/ana.21454
Weintraub D, Mamikonyan E (2019) Impulse control disorders in Parkinson’s disease. Am J Psychiatry 176(1):5–11. https://doi.org/10.1176/appi.ajp.2018.18040465
doi: 10.1176/appi.ajp.2018.18040465
pubmed: 30848949
Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KHD, Duda JE, Moberg PJ, Stern MB (2006) Dopamine agonist use is associated with impulse control disorders in Parkinson’s disease. Arch Neurol 63(7):969–973
doi: 10.1001/archneur.63.7.969
pubmed: 16831966
pmcid: 1761054
Weintraub D, Stewart S, Shea JA, Lyons KE, Pahwa R, Driver-dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V (2009) Validation of the Questionnaire for Impulsive-CompulsiveDisorders in Parkinson’s Disease (QUIP). Mov Disord 24(10):1461–1467. https://doi.org/10.1002/mds.22571.Validation
doi: 10.1002/mds.22571.Validation
pubmed: 19452562
pmcid: 2848971
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589–595. https://doi.org/10.1001/archneurol.2010.65
doi: 10.1001/archneurol.2010.65
pubmed: 20457959
Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for impulsive-compulsive disorders in Parkinson’s disease-rating scale. Mov Disord 27(2):242–247. https://doi.org/10.1002/mds.24023
doi: 10.1002/mds.24023
pubmed: 22134954